BIOGEN INC. Other Operating Income (Expense), Net
BIOGEN INC. (BIIB) reported Other Operating Income (Expense), Net of -$19.70 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2026-04-29
- BIOGEN INC. other operating income (expense), net for the quarter ending 2026-03-31 was -$19.70M.
- BIOGEN INC. other operating income (expense), net for the quarter ending 2025-09-30 was -$34.10M.
- BIOGEN INC. other operating income (expense), net for the quarter ending 2025-06-30 was -$48.70M.
- BIOGEN INC. other operating income (expense), net for the quarter ending 2025-03-31 was -$68.40M.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month |
|---|---|---|---|
| 2026-03-31 | -$19.70M 10-Q · filed 2026-04-29 | ||
| 2025-09-30 | -$34.10M 10-Q · filed 2025-10-30 | -$82.80M derived: sum of 2 quarters · filed 2025-10-30 | -$151.20M 10-Q · filed 2025-10-30 |
| 2025-06-30 | -$48.70M 10-Q · filed 2025-07-31 | -$117.10M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | -$68.40M 10-Q · filed 2026-04-29 | ||
| 2024-09-30 | -$14.80M 10-Q · filed 2025-10-30 | -$100.00M derived: sum of 2 quarters · filed 2025-10-30 | -$193.70M 10-Q · filed 2025-10-30 |
| 2024-06-30 | -$85.20M 10-Q · filed 2025-07-31 | -$178.90M 10-Q · filed 2025-07-31 | |
| 2024-03-31 | -$93.70M 10-Q · filed 2025-05-01 | ||
| 2023-09-30 | -$300.00M 10-Q · filed 2024-10-30 | -$178.80M derived: sum of 2 quarters · filed 2024-10-30 | -$248.20M 10-Q · filed 2024-10-30 |
| 2023-06-30 | $121.20M 10-Q · filed 2024-08-01 | $51.80M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | -$69.40M 10-Q · filed 2024-04-24 | ||
| 2022-09-30 | $56.00M 10-Q · filed 2023-11-08 | $484.60M derived: sum of 2 quarters · filed 2023-11-08 | $221.30M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $428.60M 10-Q · filed 2023-07-25 | $165.30M 10-Q · filed 2023-07-25 | |
| 2022-03-31 | -$263.30M 10-Q · filed 2023-04-25 | ||
| 2021-09-30 | -$502.90M 10-Q · filed 2022-10-25 | -$406.50M derived: sum of 2 quarters · filed 2022-10-25 | -$913.40M 10-Q · filed 2022-10-25 |
| 2021-06-30 | $96.40M 10-Q · filed 2022-07-20 | -$410.50M 10-Q · filed 2022-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |